Please use a PC Browser to access Register-Tadawul
UPDATE 1-Bayer sues Johnson & Johnson over marketing of prostate cancer drug
Johnson & Johnson JNJ | 240.40 | +0.32% |
Recasts; adds accusations in complaint, changes dateline to NEW YORK
NEW YORK, Feb 23 (Reuters) - Bayer BAYGn.DE sued Johnson & Johnson JNJ.N on Monday, accusing the rival drugmaker of falsely advertising a drug intended to treat prostate cancer.
According to a complaint filed in Manhattan federal court, Johnson & Johnson launched a false advertising campaign against Bayer's Nubeqa drug, in order to promote and demonstrate the alleged superiority of its own drug, Erleada.
Bayer is seeking triple damages, the recoupment of alleged ill-gotten profits, and an injunction to stop Johnson & Johnson's alleged false advertising.
Johnson & Johnson did not immediately respond to a request for comment.


